Lindus Health and the Structural Problem With the Neo-CRO Model

TL;DR

Lindus Health sold its CRO assets to Curavit and relaunched as Lindus Therapeutics, pivoting from running trials for others to in-licensing and running its own clinical-stage assets. This follows the same move TrialSpark made in 2023, now Formation Bio, while Science 37 went public above $1 billion and sold for roughly $38 million in 2024. The value of a faster trial flows to the sponsor — an earlier launch, a better success rate, and the rNPV — not to the CRO that built the engine. If you have built a better engine, owning the assets is the logical endpoint.

Lindus Health sold its CRO business on August 18 and became a drug developer. The move exposes a structural problem in the neo-CRO model: the sponsor captures most of the upside from a faster trial.

Lindus launched in 2021 as the anti-CRO. Roughly $73 million raised, with Thiel and Balderton on the cap table and Robert Langer advising. The CRO assets went to Curavit. The remaining company is now called Lindus Therapeutics. It will in-license clinical-stage assets and run the trials itself.

The founders have given no reason for the pivot.

Three well-funded attempts, none a scaled CRO today

TrialSpark made the same move in 2023 and is now Formation Bio, funded by a16z and Sanofi. Science 37 went public above $1 billion and sold to eMed in 2024 for about $38 million. Three well-funded attempts to rebuild the CRO. None operates as a scaled CRO today.

Where the economics create the pressure

The economics explain the pressure. A service business runs on mid-teens margins and receives a services multiple. An asset developer is valued on its pipeline. A company funded at a billion-dollar valuation needs upside that fees struggle to support.

Where does the value of a faster trial land? The sponsor gets an earlier launch and a better chance of success. The CRO gets a fee. The sponsor gets the rNPV.

If you have built a better engine, owning the assets is the logical endpoint.

Key takeaways

• The neo-CRO model has a structural ceiling: faster trials create value that lands with the sponsor, not the service provider.
• Three well-funded attempts to rebuild the CRO — Lindus, TrialSpark, Science 37 — and none operates as a scaled CRO today.
• A service business running on mid-teens margins cannot support a billion-dollar venture valuation on fees alone.
• The rNPV from an earlier launch accrues to whoever owns the asset, not whoever ran the trial.
• If I have built a better clinical engine, the logical endpoint is owning the pipeline, not selling access to it.